Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
14.89
-0.81 (-5.16%)
At close: Mar 3, 2026, 4:00 PM EST
14.99
+0.10 (0.67%)
Pre-market: Mar 4, 2026, 7:04 AM EST
Viatris Market Cap
Viatris has a market cap or net worth of $17.14 billion as of March 4, 2026. Its market cap has increased by 33.00% in one year.
Market Cap
17.14B
Enterprise Value
30.33B
1-Year Change
33.00%
Ranking
Category
Stock Price
$14.89
Market Cap Chart
Since December 1, 1998, Viatris's market cap has increased from $4.38B to $17.14B, an increase of 291.34%. That is a compound annual growth rate of 5.13%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 2, 2026 | 18.08B | 26.06% |
| Dec 31, 2025 | 14.34B | -3.50% |
| Dec 31, 2024 | 14.86B | 14.38% |
| Dec 29, 2023 | 12.99B | -3.74% |
| Dec 30, 2022 | 13.50B | -17.51% |
| Dec 31, 2021 | 16.36B | 61.24% |
| Dec 31, 2020 | 10.15B | -2.18% |
| Dec 31, 2019 | 10.37B | -26.57% |
| Dec 31, 2018 | 14.13B | -37.75% |
| Dec 29, 2017 | 22.70B | 11.18% |
| Dec 30, 2016 | 20.41B | -23.22% |
| Dec 31, 2015 | 26.59B | 26.03% |
| Dec 31, 2014 | 21.10B | 26.97% |
| Dec 31, 2013 | 16.62B | 48.53% |
| Dec 31, 2012 | 11.19B | 22.22% |
| Dec 30, 2011 | 9.15B | 39.85% |
| Dec 31, 2010 | 6.54B | 16.21% |
| Dec 31, 2009 | 5.63B | 86.89% |
| Dec 31, 2008 | 3.01B | -13.89% |
| Dec 31, 2007 | 3.50B | -17.30% |
| Dec 29, 2006 | 4.23B | -1.54% |
| Dec 30, 2005 | 4.30B | -9.67% |
| Dec 31, 2004 | 4.76B | -29.94% |
| Dec 31, 2003 | 6.79B | 58.86% |
| Dec 31, 2002 | 4.27B | -9.23% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Takeda Pharmaceutical Company | 58.90B |
| Zoetis | 55.34B |
| Haleon | 48.63B |
| Teva Pharmaceutical Industries | 39.43B |
| United Therapeutics | 22.08B |
| Neurocrine Biosciences | 13.27B |
| Elanco Animal Health | 13.13B |
| Regencell Bioscience Holdings | 12.97B |